Cancer Treatment Centers of America® (CTCA) has released its seventh annual summary of Patient Treatment Results, a comprehensive presentation of treatment outcomes including length of life, quality of life, the patient experience, and patient safety for 11 tumor types. Survival data from both the CTCA and SEER* (the National Cancer Institute’s Surveillance, Epidemiology and End Results Program) national databases are presented for patients whose initial diagnosis occurred between 2000 and 2015. The data were analyzed and interpreted by highly qualified medical statisticians who have no professional affiliation with CTCA.
“The publication of this report, which is one of the most comprehensive presentations of treatment results published by any cancer care provider, is a testament to CTCA’s belief in the importance of transparency and patient empowerment,” says Maurie Markman, MD, President of Medicine & Science at CTCA. “We make this information available to the public because we believe cancer patients and their caregivers should be empowered with as much information as possible to make informed decisions about their care.”
Highlights from the report include:
- Five-year survival rates for eleven tumor types including: breast, colon, esophageal, kidney, small cell lung, non-small cell lung, ovarian, pancreatic, prostate, rectal and stomach cancer;
- Quality of life data for 13 core symptoms including pain, fatigue, nausea and disturbed sleep, and six symptoms that interfere with patients’ daily functioning including mood, working around the house, walking and relations with others;
- The patient experience at CTCA hospitals compared to Press Ganey national hospital data and Press Ganey’s Top 11 Peer Oncology Providers;
- CTCA hospital patient safety and quality metrics including overall quality scores compared to normative data from the Quality Oncology Practice Initiative (QOPI) sponsored by the American Society of Clinical Oncology (ASCO).
*The SEER data represent national results over a large number of institutions and have been included for illustrative purposes. They are not intended to represent a controlled study and/or a perfect analysis of the CTCA data because of variability in the sample sizes of the two databases, the clinical condition(s) of the patient treated and other factors.